March 2023 - PsychedelicNewsWire (PNW)

FridayMar 31, 2023 2:55 pm

VIC Researcher Looks into Using Psychedelics to Combat Intergenerational Trauma

A growing body of scientific literature has revealed that psychedelic drugs such as ketamine, MDMA and psilocybin may have therapeutic potential. Researchers have found in recent years that these hallucinogens may be able to alleviate the symptoms of certain mental health disorders when accompanied by talk therapy. Furthermore, psychedelics seem to deliver these mental health benefits after relatively little doses and with few side effects. Major investors including pharmaceutical companies are now investing millions of dollars into psychedelic research to be the first to develop psychedelic-based treatments. According to Vancouver Island University researchers, tapping into indigenous knowledge will be key…

ThursdayMar 30, 2023 1:52 pm

Canadian Patients Sue Federal Government for Psilocybin Therapy Access

Psilocybin-assisted therapy has recently emerged as a potential treatment for certain mental health disorders amid a global surge in psychedelic research. Research has found that psilocybin, the main hallucinogenic agent in magic mushrooms, may be able to alleviate the effects of anxiety and depression as well as treat alcohol and nicotine-use dependence. However, most countries have classified psilocybin and most other psychedelic drugs as controlled substances with no accepted medical use. This has made it nigh impossible for mental health patients to access psilocybin without having to take part in clinical trials or shell out thousands of dollars to travel…

WednesdayMar 29, 2023 2:19 pm

Controversy Grows Over Necessity of Hallucinogenic Experiences During Psychedelic Therapy

The past few years have seen the emergence of a relatively new and controversial mode of treatment in the psychiatric sector: psychedelic-assisted therapies. As more scientists across the country have turned their attention to psychedelics and its possible benefits, a growing body of research has revealed that hallucinogenics such as ketamine, psilocybin and MDMA have the potential to treat various mental health disorders. Since the research comes when the country is in the midst of a mental health crisis and plenty of Americans are interested in safer and more effective mental health treatments, psychedelic-assisted therapies have seen a significant surge…

TuesdayMar 28, 2023 1:25 pm

Study Suggests Bad Psychedelic Trips May Confer Mental Health Benefits Too

A new paper published in the “Journal of Affective Disorders” suggests that “bad” psychedelic trips may have a positive effect on mental health. The study represents the first research to delve deeper into the psychedelic experience and break it down into subtypes. Psychedelics have been subject to increased scientific scrutiny in recent years after initial studies indicated that they may have mental health benefits. This research has revealed that psychedelic experiences can result in major neural changes that can impact mental health in positive ways. With only a single or few doses of a psychedelic such as psilocybin, ketamine or…

TuesdayMar 28, 2023 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia

Silo Pharma recently provided an update on an ongoing study delving into the potential use of SP-26 as an alternative treatment for fibromyalgia The study, which is being carried out in conjunction with Experimur, has looked into the feasibility of using a time-released, dosage-controlled formulation of ketamine as a suitable treatment for the chronic medical condition Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced…

MondayMar 27, 2023 1:19 pm

Brain Scans Give Researchers Rare Insights into Ayahuasca Effects

Ayahuasca is part of a class of chemical compounds called psychedelics that have recently been subject to intense scrutiny from the medical and scientific communities. As drug reform efforts have swept across the country, looser prohibitionist policies have allowed researchers to finally study psychedelics and their effects without fear of legal persecution. The result is a growing body of research indicating that psychedelics such as ayahuasca, psilocybin and ketamine can aid in the treatment of various mental health disorders. This led to a significant surge in psychedelic research as big pharma, and other investors threw their funds into studies to…

FridayMar 24, 2023 1:09 pm

Committee Formed to Rally Political Candidates Who Support Therapeutic Psychedelic Use

A recent increase in psychedelic research has found that psychedelics can treat mental health disorders, including anxiety, depression, suicidal thoughts and post-traumatic stress disorder. With 90% of American adults reporting that the country is in the midst of a mental health crisis, the research seems to have come at an opportune moment. The growing body of scientific literature has encouraged several lawmakers nationwide to consider measures to either decriminalize psychedelics or legalize them for medical use. Although the number of jurisdictions in America that allow psychedelic-assisted treatments is still low, it is expected to grow as more legislators pursue psychedelic…

ThursdayMar 23, 2023 2:18 pm

Study Suggests MDMA Could Boost Resilience to Chronic Social Defeat Stress

Psychedelics are poised to play a significant role in the evolution of the psychiatric industry. Hallucinogenics have revealed in several studies that they are capable of treating a variety of mental health disorders with minimal side effects. Researchers have found that psychedelics such as MDMA can aid in the treatment of social anxiety and post-traumatic stress disorder. In a recent study from Japan, scientists discovered that MDMA, also called ecstasy, could increase people’s resilience to chronic social defeat stress. The Japanese researchers created a rodent model to observe the effect of a chronic social defeat stress condition on mice and…

WednesdayMar 22, 2023 2:17 pm

Nevada Legislators File Psilocybin, MDMA Legalization Measure

Legislators in the state of Nevada have introduced a measure to legalize psilocybin and promote studies into the psychedelic while also encouraging research on MDMA. The measure, introduced by Senator Rochelle Nguyen, is mainly designed to streamline the process of conducting research on MDMA and psilocybin. It also contains language eliminating civil and criminal penalties for adults who grow, possess or share up to four ounces of psilocybin. Under the legislation, scientists would submit applications to research psychedelics to the state Department of Health and Human Services. The research part of the measure also offers legal protections against prosecution at…

TuesdayMar 21, 2023 2:04 pm

Reducing Trip Duration Crucial to Mass Adoption of Psychedelic Therapies

A growing body of scientific literature has revealed that psychedelics have the potential to treat a variety of mental disorders. Drugs such as ketamine, ecstasy (MDMA) and psilocybin have shown in clinical studies that they are capable of treating psychiatric disorders, including treatment-resistant depression, eating disorders, anxiety and substance-use disorder. As a result, major investors have increasingly turned their eyes to the nascent psychedelic sector and directed hundreds of millions of dollars toward the research and development of psychedelic-assisted therapies. One of the biggest draws of psychedelic-assisted treatments is that they kick in relatively quickly and provide long-term mental health…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: March 2023